Skip to Content

Global News Select

AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

Provided by Dow Jones

Dec 6, 2023 9:50pm

By Ben Glickman

AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 06, 2023 16:50 ET (21:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

5 Stocks to Buy While They’re Trading at Big Discounts

David Sekera, CFA May 20, 2024
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings

Dan Kemp May 17, 2024
How Anti-Obesity Drugs Are Innovating the Healthcare Market

Jessica Bebel May 16, 2024
What’s Happening In the Markets This Week

Bella Albrecht Jul 20, 2023
Why Immigration Has Boosted Job Gains and the Economy

Sarah Hansen May 16, 2024
What to Invest in During High Inflation

Margaret Giles Jul 7, 2022
Never Mind Market Efficiency: Are the Markets Sensible?

John Rekenthaler May 13, 2024
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?

Oratile Matome May 13, 2024

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.